206 related articles for article (PubMed ID: 12438698)
1. Control of biochemical reactions through supramolecular RING domain self-assembly.
Kentsis A; Gordon RE; Borden KL
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15404-9. PubMed ID: 12438698
[TBL] [Abstract][Full Text] [Related]
2. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.
Kentsis A; Dwyer EC; Perez JM; Sharma M; Chen A; Pan ZQ; Borden KL
J Mol Biol; 2001 Sep; 312(4):609-23. PubMed ID: 11575918
[TBL] [Abstract][Full Text] [Related]
3. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Brzovic PS; Keeffe JR; Nishikawa H; Miyamoto K; Fox D; Fukuda M; Ohta T; Klevit R
Proc Natl Acad Sci U S A; 2003 May; 100(10):5646-51. PubMed ID: 12732733
[TBL] [Abstract][Full Text] [Related]
4. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.
Baer R; Ludwig T
Curr Opin Genet Dev; 2002 Feb; 12(1):86-91. PubMed ID: 11790560
[TBL] [Abstract][Full Text] [Related]
5. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Brzovic PS; Rajagopal P; Hoyt DW; King MC; Klevit RE
Nat Struct Biol; 2001 Oct; 8(10):833-7. PubMed ID: 11573085
[TBL] [Abstract][Full Text] [Related]
6. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.
Cohen N; Sharma M; Kentsis A; Perez JM; Strudwick S; Borden KL
EMBO J; 2001 Aug; 20(16):4547-59. PubMed ID: 11500381
[TBL] [Abstract][Full Text] [Related]
7. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
Hashizume R; Fukuda M; Maeda I; Nishikawa H; Oyake D; Yabuki Y; Ogata H; Ohta T
J Biol Chem; 2001 May; 276(18):14537-40. PubMed ID: 11278247
[TBL] [Abstract][Full Text] [Related]
8. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a.
Gu H; Roizman B
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8963-8. PubMed ID: 12855769
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
Boutell C; Sadis S; Everett RD
J Virol; 2002 Jan; 76(2):841-50. PubMed ID: 11752173
[TBL] [Abstract][Full Text] [Related]
10. Tuning BRCA1 and BARD1 activity to investigate RING ubiquitin ligase mechanisms.
Stewart MD; Duncan ED; Coronado E; DaRosa PA; Pruneda JN; Brzovic PS; Klevit RE
Protein Sci; 2017 Mar; 26(3):475-483. PubMed ID: 27977889
[TBL] [Abstract][Full Text] [Related]
11. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains.
Mallery DL; Vandenberg CJ; Hiom K
EMBO J; 2002 Dec; 21(24):6755-62. PubMed ID: 12485996
[TBL] [Abstract][Full Text] [Related]
12. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
Ruffner H; Joazeiro CA; Hemmati D; Hunter T; Verma IM
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5134-9. PubMed ID: 11320250
[TBL] [Abstract][Full Text] [Related]
13. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.
Lai HK; Borden KL
Oncogene; 2000 Mar; 19(13):1623-34. PubMed ID: 10763819
[TBL] [Abstract][Full Text] [Related]
14. Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
Ayi TC; Tsan JT; Hwang LY; Bowcock AM; Baer R
Oncogene; 1998 Oct; 17(16):2143-8. PubMed ID: 9798686
[TBL] [Abstract][Full Text] [Related]
15. RING fingers and B-boxes: zinc-binding protein-protein interaction domains.
Borden KL
Biochem Cell Biol; 1998; 76(2-3):351-8. PubMed ID: 9923704
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E.
Volpon L; Osborne MJ; Capul AA; de la Torre JC; Borden KL
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5441-6. PubMed ID: 20212144
[TBL] [Abstract][Full Text] [Related]
17. The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.
Irminger-Finger I; Siegel BD; Leung WC
Biol Chem; 1999 Feb; 380(2):117-28. PubMed ID: 10195418
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
[TBL] [Abstract][Full Text] [Related]
19. The BRCA1 C-terminal domain: structure and function.
Huyton T; Bates PA; Zhang X; Sternberg MJ; Freemont PS
Mutat Res; 2000 Aug; 460(3-4):319-32. PubMed ID: 10946236
[TBL] [Abstract][Full Text] [Related]
20. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
Atipairin A; Canyuk B; Ratanaphan A
Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
